Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

Covid virus cells

The CATALYST Trial tested the rheumatoid arthritis treatment namilumab as a potential therapeutic to treat patients who are hospitalised with COVID-19 pneumonia and receiving 'usual' care, but who also have high levels in their blood of a protein called CRP, whose levels rise when there is inflammation in the body. Higher levels of CRP have been found to be a potential early marker to predict risk for severity of COVID-19.

Namilumab, produced by the UK-based bio-pharmaceutical company Izana Bioscience's, is an antibody that targets a 'cytokine' which is naturally secreted by immune cells in the body but, at uncontrolled levels, is believed to be a key driver of the excessive and dangerous lung inflammation seen in COVID-19 patients.

The CATALYST Trial is a collaboration between the Universities of Birmingham and Oxford and is supported by the NIHR Oxford Biomedical Research Centre (BRC). Professor Duncan Richards of NDORMS, and Dr Matt Rowland of the Nuffield Department of Clinical Neurosciences, led the Oxford arm of the study.

Between June 2020 and February 2021 the trial recruited patients aged over 16 with COVID-19 pneumonia either being treated on a ward or Intensive Care Unit (ICU) at nine NHS hospitals, including and Oxford University Hospitals (OUH) NHS Foundation Trust.

The study findings, published in The Lancet Respiratory Medicine, showed that there was a 97% probability of CRP being reduced over time in those given a single dose of namilumab, when compared with usual care alone.

The patients were monitored, and after 28 days the study also showed there were fewer deaths and more discharges from hospital or ICU in those who had been given namilumab compared to those receiving usual care alone.

By day 28, 78% (43) of the patients receiving namilumab were discharged from hospital or ICU, compared to 61% (33) of the patients given usual care. In the namilumab group, 11% (6) were still in hospital by day 28, compared to 20% (11) in the usual care group. Of those in the namilumab group, 11% (6) patients died compared to 19% (10) who died in the usual care group by day 28.

While these findings provide important proof-of-concept evidence that namilumab reduces inflammation in hospitalised COVID-19 patients, the sample size is small. Larger-scale clinical trials are required to obtain a definitive assessment of clinical outcomes, as well as to understand better the population that may benefit most.

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.